Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100765 | 0.68 | HPGDS (0.46) | HPGDSLTA4HBRD4ADRA1DADRA1A | |
| SCHEMBL3953551 | 0.68 | HPGDS (0.38) | HPGDSLTA4HBRD4 | |
| SCHEMBL611280 | 0.67 | HPGDS (0.41) | HPGDSLTA4HBRD4ADRA1DADRA1A | |
| SCHEMBL7376054 | 0.65 | HPGDS (0.40) | HPGDSLTA4HBRD4 | |
| SCHEMBL1706140 | 0.65 | LTA4H (0.35) | HPGDSLTA4H | |
| SCHEMBL4015828 | 0.65 | HPGDS (0.36) | HPGDSLTA4HBRD4 | |
| SCHEMBL1115187 | 0.65 | HPGDS (0.43) | HPGDSLTA4HBRD4ADRA1DADRA1A | |
| SCHEMBL722557 | 0.65 | LTA4H (0.64) | HPGDSLTA4HBRD4 | |
| SCHEMBL28177563 | 0.64 | LTA4H (0.45) | HPGDSLTA4HBRD4 | |
| SCHEMBL27389838 | 0.63 | HPGDS (0.34) | HPGDSLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946190-B1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE OUTGROWTH | VERTEX PHARMA (US) | 2003-09-24 | — | — | EP | claimed |
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-10-17 | — | — | US | claimed |
| CN-109803963-B | Cyano-substituted heterocycles having USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | PPARG, PPARA, PPARD | HPGDS 315/4885LTA4H 1026/4885BRD4 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.